Anzeige
Mehr »
Login
Mittwoch, 19.02.2020 Börsentäglich über 12.000 News von 619 internationalen Medien
Sind mit dieser Aktie 1.000% Gewinn möglich?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H7EV ISIN: DK0060910917 Ticker-Symbol: 1TB 
München
18.02.20
16:46 Uhr
15,900 Euro
-0,850
-5,07 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ORPHAZYME A/S Chart 1 Jahr
5-Tage-Chart
ORPHAZYME A/S 5-Tage-Chart
RealtimeGeldBriefZeit
15,600
16,200
18.02.

Aktuelle News zur ORPHAZYME Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.02.ORPHAZYME A/S: Orphazyme announces presentations at WORLDSymposium4
11.02.Nasdaq Copenhagen A/S: Orphazyme A/S - admittance to trading and official listing of new shares due to a private placement826The share capital of Orphazyme A/S has been increased. The admittance to trading and official listing will take effect as per 12 February 2020 in the ISIN below. ISIN: DK0060910917...
► Artikel lesen
11.02.ORPHAZYME A/S: Orphazyme completes registration of share capital increases of an aggregated nominal value of DKK 7,032,9372
ORPHAZYME Aktie jetzt für 4€ handeln
07.02.ORPHAZYME A/S: Orphazyme completes offering of 7,032,937 shares in a directed issue and private placement and raises approximately DKK 745,000,000 (EUR ...2
06.02.ORPHAZYME A/S: Announcement of treasury shares-
06.02.ORPHAZYME A/S: Reporting of transactions in Orphazyme's shares-
06.02.ORPHAZYME A/S: Major shareholder announcement1
06.02.ORPHAZYME A/S: Orphazyme initiates directed issue and private placement of shares2
04.02.ORPHAZYME A/S: Preliminary results for 2019 and financial outlook for 2020-
31.01.Nasdaq Copenhagen A/S: Orphazyme A/S - admittance to trading and official listing of new shares due to an issue of bonus shares724The share capital of Orphazyme A/S has been increased. The admittance to trading and official listing will take effect as per 3 February 2020 in the ISIN below. ISIN: DK0060910917...
► Artikel lesen
31.01.ORPHAZYME A/S: Capital increase of 20,650 shares (equivalent to approximately 0.10% of the existing shares) in Orphazyme A/S as a result of an issue of ...1
25.01.ORPHAZYME A/S: Resolutions passed at the Extraordinary General Meeting in Orphazyme A/S2
07.01.ORPHAZYME A/S: Reporting of transactions in Orphazyme's shares made by persons discharging managerial responsibilities5
06.01.Clinigen, Orphazyme To Make Arimoclomol Available For NPC Patients5
06.01.ORPHAZYME A/S: Orphazyme announces US Early Access Program for Niemann-Pick disease Type C3
06.01.Clinigen and Orphazyme launch an Early Access Program for arimoclomol in patients with Niemann-Pick disease type C209Clinigen Group plc (AIM: CLIN, 'Clinigen'), the global pharmaceutical and services company, has partnered with Orphazyme A/S (ORPHA.CO, 'Orphazyme'), a global biopharmaceutical company dedicated to...
► Artikel lesen
03.01.ORPHAZYME A/S: Notice to convene Extraordinary General Meeting in Orphazyme A/S2
03.01.ORPHAZYME A/S: Orphazyme reports positive arimoclomol data from open-label phase 2/3 extension in Niemann-Pick disease Type C2
19.12.19ORPHAZYME A/S: Major shareholder announcement2
18.12.19ORPHAZYME A/S: Orphazyme's arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis-
Seite:  Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1